Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Harris Associates International Equity Strategy Q1 2024 Commentary

The portfolio’s return was 0.20% (net) for the reporting period. This compares to the MSCI World ex USA Index that returned 5.59% for the same period.

FMI Funds Q1 2024 Shareholder Letter

2023's momentum carried over into Q1 2024, with growth stocks leading the charge (once again) across market caps and geographies. Click here to read more.

An Intrinsic Calculation For Smith & Nephew plc (LON:SN.) Suggests It's 34% Undervalued

Key Insights Smith & Nephew's estimated fair value is UK£15.04 based on 2 Stage Free Cash Flow to Equity Current share...

Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript

Smith & Nephew plc (NYSE:NYSE:SNN) Q1 2024 Sales/Trading Statement Conference Call May 1, 2024 3:30 AM ETCompany ParticipantsDeepak Nath - Chief...

Q1 2024 Sales/ Trading Statement Call

The following slide deck was published by Smith & Nephew plc in conjunction with this event.

With 83% ownership of the shares, Smith & Nephew plc (LON:SN.) is heavily dominated by institutional owners

Key Insights Given the large stake in the stock by institutions, Smith & Nephew's stock price might be vulnerable to...

ClearBridge International Value Strategy Q1 2024 Portfolio Manager Commentary

The ClearBridge International Value Strategy performed in-line with its MSCI EAFE benchmark during Q1 2024. Click here to read the full letter.

Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissip

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons -

Here’s Why You Should Invest in Smith & Nephew plc (SNN)

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. For the quarter ended March 31, 2024, the fund returned 0.11% compared to the MSCI World ex U.S. Index benchmark’s 5.59% return. Since its inception in September 1992, the fund returned an […]